Arvinas and Pfizer’s Breast Cancer Therapy) Receives FDA Fast Track

 Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Vepdegestrant is a novel oral PROteolysis Targeting Chimera (PROTAC®) ER degrader that is being jointly developed by Arvinas and Pfizer.

https://www.globenewswire.com/news-release/2024/02/06/2824113/0/en/Arvinas-and-Pfizer-s-Vepdegestrant-ARV-471-Receives-FDA-Fast-Track-Designation-for-the-Treatment-of-Patients-with-ER-HER2-Metastatic-Breast-Cancer.html